.jpeg)
2026-08-27 07:16:18
Brensocatib (Brinsupri) is the first FDA-approved disease-modifying therapy for non-cystic fibrosis bronchiectasis. Based on the ASPEN Phase 3 trial, it significantly reduces annual exacerbation rates and slows lung function decline. This article details patient selection, efficacy data, and safety management.
2026-08-21 03:11:31
Nintedanib (brand name OFEV) is a multi-target tyrosine kinase inhibitor that slows the decline of lung function by blocking key profibrotic signaling pathways. It is FDA-approved for idiopathic pulmonary fibrosis (IPF), progressive fibrosing interstitial lung disease (PF-ILD), and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
2026-08-10 06:51:08
Nintedanib (Ofev) is a multi-target antifibrotic agent approved for IPF, progressive fibrosing interstitial lung diseases, and systemic sclerosis-associated ILD. This article outlines its full therapeutic scope and mechanism of action.
2026-07-17 07:15:40
Learn how Macitentan (Opsumit) fits into PAH management. This guide covers dietary compatibility, critical warnings against St. John’s Wort, drug-drug interactions, and mandatory contraception requirements.
2026-06-25 06:34:59
Pretomanid is a novel anti-TB agent that kills dormant mycobacteria, enabling shorter, all-oral regimens for XDR-TB. This article covers its mechanism, BPaL trial results, safety, and clinical role.
2026-06-22 06:48:58
Brensocatib is an oral dipeptidyl peptidase-1 (DPP1) inhibitor indicated for neutrophil-mediated inflammatory diseases such as non-cystic fibrosis bronchiectasis. This article covers pre-treatment assessments, monitoring protocols, drug interactions and dosing recommendations for special populations.
2026-05-20 02:43:58
Explore the safety profile of Brensoctib, a first-in-class DPP-1 inhibitor for neutrophil-mediated inflammatory diseases. This guide details the management of dermatological, periodontal, and infection risks during treatment.
2026-05-06 03:26:04
Benralizumab (Fasenra) is generally safe for severe eosinophilic asthma, but potential risks exist. This guide covers common side effects (headache, sore throat), hypersensitivity, infection risks, and rare severe reactions, providing actionable strategies for patients and clinicians.
2026-03-30 07:09:03
Sunvozertinib, a next-gen EGFR-TKI, offers breakthrough efficacy for EGFR-mutated NSCLC patients. Designed to overcome resistance and tackle brain metastases, it provides a promising new option. Explore dosing guidelines, AE management, monitoring strategies, and long-term treatment insights.
